IP Verse

Lyophilized Liposomes - EP2768484

The patent EP2768484 was granted to Celator Pharmaceuticals on Jul 24, 2019. The application was originally filed on Oct 15, 2012 under application number EP12841616A. The patent is currently recorded with a legal status of "Revoked".

EP2768484

CELATOR PHARMACEUTICALS
Application Number
EP12841616A
Filing Date
Oct 15, 2012
Status
Revoked
Apr 27, 2024
Grant Date
Jul 24, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

D YOUNGApr 24, 2020ADMISSIBLE
SANDOZApr 23, 2020ADMISSIBLE

Patent Citations (36) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2011002982
DESCRIPTIONUS4883665
DESCRIPTIONUS4915951
DESCRIPTIONUS4927571
DESCRIPTIONUS5077056
DESCRIPTIONUS6319517
DESCRIPTIONUS7238367
DESCRIPTIONUS7850990
DESCRIPTIONUS8022279
DESCRIPTIONWO0105372
DESCRIPTIONWO03041681
DESCRIPTIONWO2005102359
DESCRIPTIONWO2007050784
DESCRIPTIONWO2007076117
DESCRIPTIONWO2008101214
DESCRIPTIONWO2009070761
DESCRIPTIONWO2009097011
DESCRIPTIONWO2010043050
DESCRIPTIONWO9965465
EXAMINATIONUS2004247660
EXAMINATIONUS5578320
INTERNATIONAL-SEARCH-REPORTUS2006110441
INTERNATIONAL-SEARCH-REPORTUS2011002982
INTERNATIONAL-SEARCH-REPORTUS8022279
INTERNATIONAL-SEARCH-REPORTWO2011092708
INTERNATIONAL-SEARCH-REPORTWO9729782
OPPOSITIONEP2508170
OPPOSITIONUS2004247660
OPPOSITIONUS2011002982
OPPOSITIONUS8022279
OPPOSITIONWO03041681
OPPOSITIONWO2005102359
OPPOSITIONWO2007076117
OPPOSITIONWO2008101214
SEARCHUS2011002982
SEARCHUS8022279

Non-Patent Literature (NPL) Citations (14) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- Vijay Joguparthi ET AL, "Liposome Transport of Hydrophobic Drugs: Gel Phase Lipid Bilayer Permeability and Partitioning of the Lactone Form of a Hydrophobic Camptothecin, DB-67", Journal of Pharmaceutical Sciences, US, (20080101), vol. 97, no. 1, doi:10.1002/jps.21125, ISSN 0022-3549, pages 400 - 420, XP055501426
OPPOSITION- A. DICKO et al., "Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin", Int. J. Pharm., (20100200), vol. 391, no. 1-2, pages 248 - 259, XP027018892-
OPPOSITION- DICKO A ET AL., PHARM RES, vol. 25, no. 7, 2008, pages 1702 - 1713, XP019613128-
OPPOSITION- Dicko, A. ; Kwak, S. ; Frazier, A.A. ; Mayer, L.D. ; Liboiron, B.D., "Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, NL, (20100531), vol. 391, no. 1-2, ISSN 0378-5173, pages 248 - 259, XP027018892-
OPPOSITION- NOUNOU MM et al., DARU, (20050000), vol. 13, no. 4, pages 133 - 143, XP055716488-
OPPOSITION- Stark, B. ; Pabst, G. ; Prassl, R., "Long-term stability of sterically stabilized liposomes by freezing and freeze-drying: Effects of cryoprotectants on structure", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES., ELSEVIER, AMSTERDAM., NL, NL, (20101120), vol. 41, no. 3-4, ISSN 0928-0987, pages 546 - 555, XP027369053-
OPPOSITION- Helmut Hauser, Et Al, "Stabilization of Small, Unilamellar Phospholipid Vesicles by Sucrose during Freezing And Dehydration", Advances in Experimental Medicine and Biology, (19880101), vol. 238, pages 71 - 80, XP055716496
OPPOSITION- J.H. CROWE et al., "Factors affecting the stability of dry liposomes", Biochim. Biophys. Acta, (19880407), vol. 939, no. 2, pages 327 - 334, XP023510045
OPPOSITION- Tardi, P.G. Gallagher, R.C. Johnstone, S. Harasym, N. Webb, M. Bally, M.B. Mayer, L.D., "Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo", BBA - Biomembranes, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20070222), vol. 1768, no. 3, doi:10.1016/j.bbamem.2006.11.014, ISSN 0005-2736, pages 678 - 687, XP005900726
OPPOSITION- Hyun Pyo Kim; Brigitte Gerhard; Troy O. Harasym; Lawrence D. Mayer; Donna E. Hogge;, "Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells", EXPERIMENTAL HEMATOLOGY, Elsevier Inc., US, US, (20110404), vol. 39, no. 7, doi:10.1016/j.exphem.2011.04.001, ISSN 0301-472X, pages 741 - 750, XP028244226
OPPOSITION- Qiu, L. ; Jing, N. ; Jin, Y., "Preparation and in vitro evaluation of liposomal chloroquine diphosphate loaded by a transmembrane pH-gradient method", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, NL, (20080901), vol. 361, no. 1-2, doi:10.1016/j.ijpharm.2008.05.010, ISSN 0378-5173, pages 56 - 63, XP023316059
OPPOSITION- C. CHEN et al., J. Control. Rel., (20100319), vol. 142, no. 3, pages 299 - 311, XP026930148
OPPOSITION- E.J. FELDMAN et al., "First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia", J. Clin. Oncol., (20110310), vol. 29, no. 8, pages 979 - 985, XP055384118
OPPOSITION- A. DICKO et al., "Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo", Exp. Opin. Drug Delivery, (20101200), vol. 7, no. 12, pages 1329 - 1341, XP055706354

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents